Alder’s Migraine Treatment Shines in Phase 2b

Alder Biopharmaceuticals’ migraine drug ALD403 met primary and secondary endpoints in a Phase 2b study.

A single intravenous injection of the compound prevented or reduced migraines for a 12-week period in 27 percent to 41 percent of patients who experience chronic migraines.

Alder plans to enter late-stage trials of a self-injected formulation to complement the infusion formulations evaluated in the PROMISE 1 and 2 trials.